Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections

Most Products Remain In Preclinical Development

Executive Summary

Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.

Monkeypox Is A Different Drug Development Ballgame From COVID-19

SIGA chief scientific officer Dennis Hruby spoke with Scrip about how the company is developing its drug, Tpoxx, to address the monkeypox outbreak.

J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain

The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147061

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel